Biological treatments for systemic lupus erythematosus

被引:6
|
作者
Isenberg, D [1 ]
Leckie, MJ
机构
[1] UCL, Middlesex Hosp, Ctr Rheumatol, London WIP 9PG, England
[2] Hammersmith Hosp, Rheumatol Unit, London, England
关键词
SLE; cytokines; autoantibodies;
D O I
10.1080/030097402320318350
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There have been many recent advances in therapeutic approaches to systemic lupus erythematosus (SLE). The roles of cyclophosphamide, hydroxychloroquine, methotrexate and hormonal treatments in the management of SLE have been investigated in recent randomised controlled trials (1). However, although these pharmacological agents have a role to play in some patients with lupus, broad based effects have led to problems with side effects and adverse reactions. For this reason, more specific therapies are urgently required. Such strategies currently under evaluation include altering the cytokine balance, reducing T cell activation and inducing tolerance, blocking T cell costimulatory molecules, reducing auto-antibody production from B cells, targetting specific genes and stem cell transplantation. These are known as "biological" treatments as their aim is to alter patho-physiological processes occurring in the diseased state. This review will focus on the biological therapies currently under investigation-with particular attention on the cytokine-directed therapies.
引用
收藏
页码:187 / 191
页数:5
相关论文
共 50 条
  • [21] Immunosuppressor and immunomodulator treatments for severe systemic lupus erythematosus
    Guillevin, L
    ANNALES DE MEDECINE INTERNE, 1996, 147 (07): : 498 - 505
  • [22] The first biological approved to treat systemic lupus erythematosus
    Fiehn, Christoph
    IMMUNOTHERAPY, 2011, 3 (11) : 1293 - 1294
  • [23] Systematic review of treatments for the gastrointestinal manifestations of systemic lupus erythematosus
    Williamson, Luke
    Hao, Yanjie
    Basnayake, Chamara
    Oon, Shereen
    Nikpour, Mandana
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 69
  • [24] Approach to vaccination in systemic lupus erythematosus on biological treatment
    Yildirim, Resit
    Oliveira, Tatiana
    Isenberg, David Alan
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (09) : 1123 - 1129
  • [26] Patients’ Preferences for Systemic Lupus Erythematosus Treatments—A Discrete Choice Experiment
    Hannah Collacott
    Andrea Phillips-Beyer
    Nicolas Krucien
    Bruno Flamion
    Kevin Marsh
    The Patient - Patient-Centered Outcomes Research, 2024, 17 : 287 - 300
  • [27] Severe erosive arthropathy requiring surgical treatments in systemic lupus erythematosus
    Kitaori, Toshiyuki
    Ito, Hiromu
    Yoshitomi, Hiroyuki
    Aoyama, Tomoki
    Fujii, Takao
    Mimori, Tsuneyo
    Nakamura, Takashi
    MODERN RHEUMATOLOGY, 2009, 19 (04) : 431 - 436
  • [28] PATIENT PREFERENCES FOR SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENTS: A DISCRETE CHOICE EXPERIMENT
    Collacott, H.
    Phillips-Beyer, A.
    Krucien, N.
    Marsh, K.
    Flamion, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 264 - 264
  • [29] CLINICO-BIOLOGICAL ISSUES OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
    Belibou, Iulia Codruta
    Ancuta, Codrina
    Miu, Smaranda
    Ancuta, E.
    Pastragus, Carmen
    Chirieac, Rodica
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2012, 116 (01): : 83 - 89
  • [30] Biological impact of iberdomide in patients with active systemic lupus erythematosus
    Lipsky, Peter E.
    Van Vollenhoven, Ronald
    Doerner, Thomas
    Werth, Victoria P.
    Merrill, Joan T.
    Furie, Richard
    Petronijevic, Milan
    Zamora, Benito Velasco
    Majdan, Maria
    Irazoque-Palazuelos, Fedra
    Terbrueggen, Robert
    Delev, Nikolay
    Weiswasser, Michael
    Korish, Shimon
    Stern, Mark
    Hersey, Sarah
    Ye, Ying
    Gaudy, Allison
    Liu, Zhaohui
    Gagnon, Robert
    Tang, Shaojun
    Schafer, Peter H.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (08) : 1136 - 1142